Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus
Objetive: Type 2 diabetes mellitus (DM2) and osteoporosis are diseases associated with a pro‐inflammatory environment, the prevention of which through new therapeutic strategies could prevent their development. However, there are few studies that evaluate the inflammatory profile of osteoporosis in...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/302970 |
| Acceso en línea: | http://hdl.handle.net/10261/302970 |
| Access Level: | acceso abierto |
| Palabra clave: | Diabetes mellitus tipo 2 Osteoporosis Inflamación Citocinas |
| id |
ES_de431b3d8a9e97af1afd239acdff0dfb |
|---|---|
| oai_identifier_str |
oai:digital.csic.es:10261/302970 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus Entorno inflamatorio diferencial en pacientes con osteoporosis y diabetes mellitus tipo 2 |
| title |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| spellingShingle |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus Muñoz-Torres, M. Diabetes mellitus tipo 2 Osteoporosis Inflamación Citocinas |
| title_short |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| title_full |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| title_fullStr |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| title_full_unstemmed |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| title_sort |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus |
| dc.creator.none.fl_str_mv |
Muñoz-Torres, M. Carazo-Gallego, A. Jiménez-López, José Carlos Avilés-Pérez, M.D. Díaz-Arco, S. Lozano-Alonso, S. Lima Cabello, Elena Alché Ramírez, Juan de Dios Reyes-García, R. Morales-Santana, Sonia |
| author |
Muñoz-Torres, M. |
| author_facet |
Muñoz-Torres, M. Carazo-Gallego, A. Jiménez-López, José Carlos Avilés-Pérez, M.D. Díaz-Arco, S. Lozano-Alonso, S. Lima Cabello, Elena Alché Ramírez, Juan de Dios Reyes-García, R. Morales-Santana, Sonia |
| author_role |
author |
| author2 |
Carazo-Gallego, A. Jiménez-López, José Carlos Avilés-Pérez, M.D. Díaz-Arco, S. Lozano-Alonso, S. Lima Cabello, Elena Alché Ramírez, Juan de Dios Reyes-García, R. Morales-Santana, Sonia |
| author2_role |
author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
European Commission Ministerio de Economía, Industria y Competitividad (España) Junta de Andalucía Fundación Española de Investigación Ósea y del Metabolismo Mineral Sociedad Española de Endocrinología y Nutrición Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72] |
| dc.subject.none.fl_str_mv |
Diabetes mellitus tipo 2 Osteoporosis Inflamación Citocinas |
| topic |
Diabetes mellitus tipo 2 Osteoporosis Inflamación Citocinas |
| description |
Objetive: Type 2 diabetes mellitus (DM2) and osteoporosis are diseases associated with a pro‐inflammatory environment, the prevention of which through new therapeutic strategies could prevent their development. However, there are few studies that evaluate the inflammatory profile of osteoporosis in patients with DM2. This study focuses on evaluating the inflammatory immune response through serum concentrations of nine cytokines, two of them anti‐inflammatory (IL‐10, IL‐5) and six pro‐inflammatory (IL‐2, IL‐6, IL‐12 (p70), IL‐17A, TNFα and IFNγ) in 163 individuals with DM2 and 47 controls. A subpopulation, made up of 43 DM2 patients without osteoporosis, and 33 with osteoporosis, was analyzed in greater depth at the level of bone parameters. Furthermore, we have assessed the calciotropic hormones, bone remodeling markers, bone mineral density and vertebral fractures in the population, and we have analyzed the relationship of the cytokines tested with DM2, osteoporosis and prevalent vertebral fractures. Patients with DM2 had significantly higher serum concentrations of IL‐10 compared to the control group (0.5±1 vs. 0.14±0.3 pg/ml; p=0.016) and the levels of IL12 p70 were shown lower in patients with DM2 compared to controls (2.9±1.6 vs. 3.9±3.1 pg/ml; p=0.027). In the group of patients with DM2 and osteoporosis, the levels of the cytokine IL‐6 were elevated compared to the group with DM2 without osteoporosis (10.9±14.6 vs. 4.5±7.0; p=0.017). An association of IL‐5 was also observed, with its lowest levels in the DM2 group with osteoporosis (1.7±0.2 vs. 3.8±0.6; p=0.032). Furthermore, IL‐5 showed a direct correlation with the levels of the bone formation biomarker alkaline bone phosphatase (r=0.277, p=0.004) in the subpopulation of patients with DM2. The rest of cytokines did not show significant differences. In conclusion, our findings indicate that in our study population, patients with DM2 compared to healthy subjects present an inflammatory profile opposite to what is expected in a hyperglycemic situation, probably as a compensatory response to the inflammation caused. The cytokine profile is modified in the subpopulation of diabetic patients, depending on the presence of osteoporosis. In this case, the inflammatory profile in the presence of osteoporosis is consistent with the expected response. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2023 2023 2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10261/302970 |
| url |
http://hdl.handle.net/10261/302970 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
#PLACEHOLDER_PARENT_METADATA_VALUE# info:eu-repo/grantAgreement/MINECO//RYC-2014-16536 http://dx.doi.org/10.4321/S1889-836X2022000100004 Sí |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Sociedad Española de Investigaciones Óseas y Metabolismo Mineral |
| publisher.none.fl_str_mv |
Sociedad Española de Investigaciones Óseas y Metabolismo Mineral |
| dc.source.none.fl_str_mv |
reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| collection |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869421958241714176 |
| spelling |
Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitusEntorno inflamatorio diferencial en pacientes con osteoporosis y diabetes mellitus tipo 2Muñoz-Torres, M.Carazo-Gallego, A.Jiménez-López, José CarlosAvilés-Pérez, M.D.Díaz-Arco, S.Lozano-Alonso, S.Lima Cabello, ElenaAlché Ramírez, Juan de DiosReyes-García, R.Morales-Santana, SoniaDiabetes mellitus tipo 2OsteoporosisInflamaciónCitocinasObjetive: Type 2 diabetes mellitus (DM2) and osteoporosis are diseases associated with a pro‐inflammatory environment, the prevention of which through new therapeutic strategies could prevent their development. However, there are few studies that evaluate the inflammatory profile of osteoporosis in patients with DM2. This study focuses on evaluating the inflammatory immune response through serum concentrations of nine cytokines, two of them anti‐inflammatory (IL‐10, IL‐5) and six pro‐inflammatory (IL‐2, IL‐6, IL‐12 (p70), IL‐17A, TNFα and IFNγ) in 163 individuals with DM2 and 47 controls. A subpopulation, made up of 43 DM2 patients without osteoporosis, and 33 with osteoporosis, was analyzed in greater depth at the level of bone parameters. Furthermore, we have assessed the calciotropic hormones, bone remodeling markers, bone mineral density and vertebral fractures in the population, and we have analyzed the relationship of the cytokines tested with DM2, osteoporosis and prevalent vertebral fractures. Patients with DM2 had significantly higher serum concentrations of IL‐10 compared to the control group (0.5±1 vs. 0.14±0.3 pg/ml; p=0.016) and the levels of IL12 p70 were shown lower in patients with DM2 compared to controls (2.9±1.6 vs. 3.9±3.1 pg/ml; p=0.027). In the group of patients with DM2 and osteoporosis, the levels of the cytokine IL‐6 were elevated compared to the group with DM2 without osteoporosis (10.9±14.6 vs. 4.5±7.0; p=0.017). An association of IL‐5 was also observed, with its lowest levels in the DM2 group with osteoporosis (1.7±0.2 vs. 3.8±0.6; p=0.032). Furthermore, IL‐5 showed a direct correlation with the levels of the bone formation biomarker alkaline bone phosphatase (r=0.277, p=0.004) in the subpopulation of patients with DM2. The rest of cytokines did not show significant differences. In conclusion, our findings indicate that in our study population, patients with DM2 compared to healthy subjects present an inflammatory profile opposite to what is expected in a hyperglycemic situation, probably as a compensatory response to the inflammation caused. The cytokine profile is modified in the subpopulation of diabetic patients, depending on the presence of osteoporosis. In this case, the inflammatory profile in the presence of osteoporosis is consistent with the expected response.Este estudio ha sido financiado con las ayudas para realización de proyectos otorgadas por las fundaciones FEIOMM y SEEN, así como por el proyecto de la Consejería de Salud y familias PI-0450-2019. Además, el Dr. Jiménez-López agradece la financiación al programa de investigación Europeo Marie Curie (FP7--PEOPLE-2011-IOF, número de referencia PIOF-GA-2011-301550), así como al Ministerio de Economía, Industria y Competitividad por el proyecto del programa Ramón y Cajal (RYC-2014-16536) y el proyecto BFU2016-77243-P.Sociedad Española de Investigaciones Óseas y Metabolismo MineralEuropean CommissionMinisterio de Economía, Industria y Competitividad (España)Junta de AndalucíaFundación Española de Investigación Ósea y del Metabolismo MineralSociedad Española de Endocrinología y NutriciónConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320222023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/302970reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MINECO//RYC-2014-16536http://dx.doi.org/10.4321/S1889-836X2022000100004Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3029702026-05-22T06:33:51Z |
| score |
15,812455 |